Krystal Biotech Inc

NASDAQ:KRYS   12:19:02 PM EDT
52.93
+0.94 (+1.81%)
Products, Regulatory, Earnings Announcements

Krystal Biotech Announces Topline Results From GEM-3 Pivotal Trial Of Vyjuvek In Patients With Dystrophic Epidermolysis Bullosa

Published: 11/29/2021 12:25 GMT
Krystal Biotech Inc (KRYS) - Krystal Biotech Announces Positive Topline Results From Gem-3 Pivotal Trial of Vyjuvek™ in Patients With Dystrophic Epidermolysis Bullosa.
Krystal Biotech Inc - Gem-3 Trial Met Its Primary Endpoint of Complete Wound Healing at Six-month Timepoints.
Krystal Biotech Inc - Gem-3 Trial Met Its Secondary Endpoint of Complete Wound Healing at Three-month Timepoints.
Krystal Biotech Inc - Vyjuvek Was Well Tolerated, With No Drug-related Serious Adverse Events Or Discontinuations.
Krystal Biotech Inc - Bla on Track to Be Submitted to U.S. Food and Drug Administration in H1 2022.
Krystal Biotech Inc - Currently Constructing Its Second, Larger, Facility Astra, Which is Expected to Come On-line in 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.72

Next Quarter Revenue Guidance is expected to be $0.03 Million
Next Quarter EPS Guidance is expected to be -$0.79

More details on our Analysts Page.